BGI Genomics Co., Ltd. (SHE:300676)

Market Cap	14.61B -21.2%
Revenue (ttm)	3.72B +0.2%
Net Income	-545.01M
EPS	-1.31
Shares Out	383.85M
PE Ratio	n/a
Forward PE	136.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,951,340
Open	37.06
Previous Close	36.92
Day's Range	36.00 - 38.41
52-Week Range	32.55 - 65.00
Beta	0.76
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2026

About BGI Genomics

BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exome sequencing; epigenetics whole genome bisulfite sequencing and ChIp-Seq; and metagenomics and 16S/18S/ITS sequencing. It also provides RNA sequencing,...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1999
• Employees: 3,580
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300676

Financial Performance

In 2025, BGI Genomics's revenue was 3.71 billion, a decrease of -4.18% compared to the previous year's 3.87 billion. Losses were -616.66 million, -31.69% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 2, 2026

Data Sources Report a data error